MKC-3946 is primarily investigated for its potential in cancer therapy, particularly in targeting specific pathways involved in tumor growth and survival. It has shown promise in preclinical studies as an inhibitor of certain kinases that play a critical role in cancer cell proliferation and resistance to apoptosis. Researchers are exploring its efficacy in treating hematologic malignancies and solid tumors, focusing on its ability to enhance the effectiveness of existing chemotherapeutic agents. Additionally, MKC-3946 is being studied for its potential to overcome drug resistance in cancer cells, making it a candidate for combination therapies. Its application extends to improving patient outcomes by targeting molecular mechanisms that are often dysregulated in various cancers.